The purpose of this study was to investigate the efficacy and safety of enoxaparin in preventing venous and arterial thromboembolism related events after primary total knee arthroplasty (TKA) in Asian patients. Four hundred twenty nine patients (621 TKAs) did not receive thromboprophylaxis after TKA and 907 patients (1,336 TKAs) received enoxaparin after the procedure. We assessed clinically significant venous and arterial thromboembolism related events and bleeding complications. Total thromboembolism related events occurred in 13 patients (3.03%) without thromboprophylaxis and 17 patients (1.87%) with enoxaparin (P = 0.183). Our study showed that the incidence of clinically significant thromboembolism related events after TKA was very low in Asian patients. Enoxaparin had no benefits in reducing thromboembolism related events in Asian patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.arth.2013.04.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The objectives were to evaluate the effectiveness and safety of a single preoperative dose of intravenous tranexamic acid (TXA) in reducing perioperative blood loss and requirement for transfusion in patients undergoing hip hemiarthroplasty for femoral neck fracture. A double-blind randomized controlled trial was conducted in 140 patients with hip fracture. After randomization, 68 patients received a single dose of 1 gr of intravenous TXA at the start of the surgery (TXA group), and 72 received a placebo treatment (placebo group).
View Article and Find Full Text PDFThe efficacy and safety of indobufen in patients with ischemic cardiovascular or cerebrovascular diseases: systematic review and meta-analysis.
Front Cardiovasc Med
January 2025
Department of Cardiology, Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Objective: This meta-analysis aims to evaluate the safety and efficacy of indobufen in the treatment of cardiovascular diseases, cerebrovascular diseases, and thromboembolic disorders. The primary focus is on the incidence of major adverse cardiovascular events (MACE), thrombosis, bleeding events, and adverse reactions. The results are intended to provide a reference for the clinical application of indobufen and suggest directions for further large-scale, multi-center, prospective studies.
View Article and Find Full Text PDFBalancing the risks: continuous vs. interrupted anticoagulation during TAVI - what does the evidence say?
Thromb J
January 2025
Department of Medicine, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.
Anticoagulation therapy is a critical component of post-transcatheter aortic valve implantation (TAVI) management, aimed at reducing the risk of thromboembolic events and mortality. This review examines the efficacy of continuous versus interrupted anticoagulation strategies in TAVI patients, focusing on mortality, stroke rates, and composite events. A literature review was conducted, analyzing recent studies that evaluate the impact of different anticoagulation regimens on clinical outcomes in TAVI patients.
View Article and Find Full Text PDFInvestigating the dual causative pathways linking immune cells and venous thromboembolism via Mendelian randomization analysis.
Thromb J
January 2025
Department of Vascular Surgery, Huadong Hospital, Fudan University, Shanghai, 200040, China.
Background: Venous thromboembolism (VTE) is a common vascular disease with a significant global burden, influenced by multiple factors, such as genetic, environmental, and immune components. Immune responses and shifts in immune cell profiles are closely linked to the development and progression of VTE, yet current studies are limited by confounding factors and reverse causation. To address these limitations, this study uses Mendelian randomization to explore the causal relationship between immune cell traits and VTE, aiming to provide insights into underlying mechanisms.
View Article and Find Full Text PDFAssessing the Comparative Efficacy and Safety of Warfarin and Rivaroxaban for Cancer Associated Thrombosis: Experience From a Resource Limited Setting.
Cancer Rep (Hoboken)
January 2025
School of Medicine; College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Background: Thromboembolic events are a common cause of morbidity and mortality in patients with cancer. While direct-acting oral anticoagulants (DOACs) have been established as the preferred agents of anticoagulation in most patients with cancer, data in resource-limited settings is limited.
Aims: The study aims to assess the comparative efficacy and safety of warfarin and rivaroxaban for cancer-associated thrombosis (CAT) in a resource-limited setting.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!